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Transgenic mouselmark of chronic pancreatitis, currently an incurable disease. Pancreatitis ﬁbrosis
is caused by deposition of extracellular matrix (ECM) and the underlying pathological mechanism remains
unclear. In addition to its broad biological activities, TGF-β is a potent pro-ﬁbrotic factor and many in vitro
studies using cell systems have implicated a functional role of TGF-β in the pathogenesis of pancreatic
ﬁbrosis. We analyzed the in vivo role of TGF-β pathway in pancreatic ﬁbrosis in this study. Smad7, an
intracellular inhibitory protein that antagonizes TGF-β signaling, was speciﬁcally expressed in the pancreas
using a transgenic mouse model. Chronic pancreatitis was induced in the mouse with repeated
administration of cerulein. Smad7 expression in the pancreas was able to signiﬁcantly inhibit cerulein-
induced pancreatic ﬁbrosis. Consistently, the protein levels of collagen I and ﬁbronectin were decreased in
the Smad7 transgenic mice. In addition, α-smooth muscle actin, a marker of activated pancreas stellate cells,
was reduced in the transgenic mice. Taken together, these data indicate that inhibition of TGF-β signaling by
Smad7 is able to protect cerulein-induced pancreatic ﬁbrosis in vivo.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Transforming growth factor beta (TGF-β) is a multipotent cytokine
that plays important roles in the regulation of cell growth, cell
differentiation, apoptosis, immune response, and cancinogenesis [1,2].
In addition, TGF-β has been shown to be a potent pro-ﬁbrotic factor
that is implicated in the pathogenesis of ﬁbrosis in the liver, pancreas,
lung, and other organs [3–5]. TGF-β ligand initiates its downstream
signaling by binding to type I and type II receptors, followed by
activation of downstream Smad proteins. Three classes of Smad
proteins are involved in the signal transduction and regulation of TGF-
β family receptors: receptor-regulated Smad (R-Smad), Co-mediator
Smad (Co-Smad or Smad4), and inhibitory Smad (I-Smad) [6]. R-
Smads are phosphorylated by the serine/theronine kinase domain of
type I receptor. Activated R-Smad and Smad4 form a protein complex
that is translocated into the nucleus and regulates the transcription of
target genes. Smad7 belongs to the I-Smad subfamily which
negatively regulates TGF-β signaling by competing with R-Smads for
receptor binding [7].
The mechanism of chronic pancreatitis is obscure and the disease
cannot be cured at present. Chronic pancreatitis is characterized by
the gradual loss of exocrine and endocrine cells with the development86 21 54920291.
ll rights reserved.of ﬁbrosis. The degradative process is thought to be caused by the
injury of epithelium and the resulting recruitment of inﬂammatory
cells [8]. Along with the disappearance of exocrine compartment,
mainly acinar cells, the increasingly formed extracellular matrix
(ECM) takes over the place, leading to ﬁbrosis [9].
The mechanism of ﬁbrosis is poorly understood. Recent evidence
suggests that TGF-β promotes pancreatic ﬁbrogenesis. TGF-β activates
pancreas stellate cells (PSCs), which are thought to be the culprit of
ﬁbrosis [10,11], in both autocrine and paracrine manners [9,12]. The
activated PSCs secret ECM such as type I collagen, ﬁbronectin, laminin,
andMMPs [13–15]. It has been shown thatα-smooth muscle actin (α-
SMA) is a marker of PSCs. Transgenic mice overexpressing TGF-β in
islet cells developed exocrine pancreas ﬁbrosis [16]. Consistently, TGF-
β expression was observed in acinar cells adjacent to ﬁbrotic areas in
human chronic pancreatitis tissues [10].
Recent studies have revealed that inhibition of TGF-β signaling
results in improvement of ﬁbrosis. Inhibition of TGF-β by a neutraliz-
ing antibody reduced ECM production in cerulein-induced pancrea-
titis in rats [17]. Overexpression of a dominant-negative mutant form
of TGF-β type II receptor also reduced pancreatic ﬁbrosis [18,19]. Taken
together, these studies have revealed that TGF-β contributes to
ﬁbrogenesis in pancreas and inhibition of TGF-β signaling has a
beneﬁcial role to improve pancreatic ﬁbrogenesis. However, whether
or not Smad7 is implicated in pancreatic ﬁbrogenesis has not been
investigated. We hypothesize that Smad7 could decrease pancreatic
Fig. 1. Characterization of Smad7 transgenic mice. (A) Representative data showing the
result of genomic PCR with mouse tails. The samples positive for Smad7 transgene are
marked in the bottom. The DNA molecular size marker is also shown in the picture. (B)
Western blotting analysis with pancreas of the mice. The samples with detectable
expression of the Myc-tagged Smad7 are labeled in the bottom. The Smad7 control was
from cell lysate with overexpression of a Myc-tagged Smad7. (C) Pancreas-speciﬁc
expression of exogenous Smad7 in the transgenic mouse. Different tissues were isolated
from a Smad7 transgenic mouse as indicated and protein preparation from these tissues
was used in Western blotting with an anti-Myc antibody.
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using a transgenic mouse with pancreas-speciﬁc expression of Smad7.
As described in this study, we found that overexpression of Smad7 is
able to ameliorate pancreatic ﬁbrosis induced by chronic administra-
tion of cerulein.
2. Materials and method
2.1. Animals
The Smad7 transgenic mice were generated as previously
described [20]. All transgenic mice were maintained by crossing
with C57BL/6J strain mice.
2.2. Identiﬁcation of transgenic mice
Genomic DNA was extracted from a 2-mm tail biopsy: The tissues
were incubated with 50 mmol/L NaOH at 100 °C for 1 h, neutralized
with 1 M Tris–HCl (pH 8.0). The samples were centrifuged and the
supernatant was used in PCR genotyping with primers 5′-
CTTTGTACTTTCATGTCACCTGTGC-3′ and 5′-CGCCGGACGAGCGCA-
GATCGTT-3′.
2.3. Tissue harvest, protein extraction, and Western blotting analysis
Pancreas and other tissues were removed and washed with cold
PBS, homogenized, and solubilized in cold RIPAbuffer (50mMTris–HCl
at pH 7.4, 1% Nonidet P-40, 0.25% sodium deoxycholate, 150 mM NaCl,
and1mMEDTA) containingprotease inhibitor cocktail (Sigma-Aldrich,
Saint Louis, MO, USA). Proteins from various tissues were resolved by
SDS/PAGE, and transferred to PVDF membranes (Millipore, Billerica,
MA, USA). The Myc-tagged Smad7 were detected by Western blotting
using a mouse anti-Myc antibody (Santa Cruz, Santa Cruz, CA, USA).
2.4. Mouse experimental protocol
Female and male mice of 2-month-old were treated with cerulein
to induce chronic pancreatitis as previously described [21]. Brieﬂy,
50 μg/kg cerulein (BACHEM California Inc., Torrance, CA, USA) was
injected intraperitoneally every hour for 5 consecutive times. Such
injection was repeated for 3 days per week up to a total of 8 weeks.
Saline was injected as control. Mice were sacriﬁced four days after the
ﬁnal cerulein treatment. The pancreas was swiftly removed and ﬁxed
in Bouin's solution (75% picric acid saturated aqueous solution, 25% of
40% formaldehyde, and 5% glacial acetic acid).
2.5. Histological analysis
Mouse pancreas specimens were ﬁxed in Bouin's solution over-
night at room temperature and embedded in parafﬁn using standard
techniques. The parafﬁn-embedded sections (5 μm) were stained with
hematoxylin/eosin (H&E) to determine the histopathological features.
2.6. Immunohistochemistry and quantitative analysis
The immunohistochemistry was done on 5 μm sections using
SABC (mouse/rabbit IgG) kit according to the manufacturer's
instructions (Boster, Wuhan, Hubei, China). The primary antibodies
used were as follows: rabbit anti-collagen I antibody (1:500,
Abcam, Cambridge, MA, USA), rabbit anti-α-SMA antibody
(1:1000, Abcam), Mouse anti-ﬁbronectin antibody (1:500, Abcam).
Densitometric analysis of α-SMA protein expression was performed
manually. In brief, three ﬁelds per α-SMA-stained pancreatic
sections (5 sections for each experimental group) were randomly
selected at 200× magniﬁcation by an examiner blinded to the
treatment groups. The α-SMA positive cells were examined todetermine the relative level of α-SMA staining. Fibronectin staining
was used to analyze ﬁbrosis area. Four non-overlapping ﬁelds per
ﬁbronectin-stained pancreatic sections (at least 3 sections for each
experimental group) were randomly selected at 200× magniﬁcation
by an investigator who was unaware of the sample identity. The
ﬁbrosis area was calculated by the image processing software
ImageJ (developed by NIH and downloaded from http://rsbweb.nih.
gov/ij/). Brieﬂy, the images were converted to HSB stack with
saturation set at 155 as MinThreshold and 255 as MaxThreshold to
segment the ﬁbronectin-stained area. The percentage of area
within the threshold in the whole image was measured as the
ﬁbrosis area.
3. Results and discussion
In order to determine whether or not Smad7 plays a role in
pancreatic ﬁbrosis, we generated a transgenic mouse model with
pancreatic expression of Smad7 using the strategy as previously
described by us [20]. The plasmid used for the transgenic mouse
contains a −205/+8 bp rat elastase I gene promoter/enhancer, a Smad7
cDNA with a Myc-tag at its N terminus, and an SV40 poly(A) tail [20].
The plasmid was linearized and microinjected into the zygote with
C57BJ/6L (female) and CBA (male) background. From 155 offspring, we
found that 24mice carried the Smad7 transgene and only two of them
expressed the exogenous Smad7 gene. These two founders were
crossed with mice of C57BJ/6L background to generate Smad7
transgenic mice for the study. The transgenic mice were identiﬁed
by genomic PCR (Fig. 1A) to determine the presence of the Smad7
Fig. 2. Pathological changes in pancreas after repetitive injections of cerulean. Wild type mice were treated with saline (A) or cerulein for 4 weeks (B), or cerulein for 8 weeks (C to F).
Note that pancreatic ﬁbrosis occurred after 4 weeks' cerulein treatment, and was aggravated after 8 weeks' cerulein administration. The characteristics of chronic pancreatitis were
apparent, including atrophy of acinar cells (B and C), hemorrhage (D, arrow) and inﬂammatory cell inﬁltration (E, arrowhead), and acinar-to-ductal metaplasia (E and F, arrows).
Magniﬁcation: ×100 for A, B and C, ×200 for D, E, and ×400 for F.
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exogenous Smad7 with a Myc tag (Fig. 1B). Consistent with previous
report [20], the exogenous Smad7 was speciﬁcally expressed in the
pancreas, but not in other tissues (Fig. 1C).
We induced chronic pancreatitis by repeated induction of acute
pancreatitis as previously reported [19,21]. Considering that prema-
lignant ductal lesions occurs the Smad7 transgenic mice 6 months
[20], we chose 2-month-oldmice for induction of chronic pancreatitis.
Injection of cerulein for 4 weeks provoked loss of acinar cells and ECM
deposition in wild type mice (Fig. 2). Pancreatic ﬁbrosis occurred after
another 4 weeks' injection with the hallmarks of chronic pancreatitis
(Fig. 2C), accompanied by hemorrhage and inﬂammatory cell inﬁltra-
tion (Fig. 2D). We also observed acinar-to-ductal metaplasia (Fig. 2E
and F), another important pathological change in which acinar cells
lose their characteristic zymogen granules and acquire the features ofFig. 3. Cerulein-induced chronic pancreatitis was ameliorated by exogenous expression of Sm
with saline (A and E) or cerulein (C to E, F to H) for 8 weeks. Note that the overall pathologica
Each picture represents the result from different mouse. Magniﬁcation: ×100.duct cells. Taken together, these data suggest that repeated admin-
istration of cerulein was able to induce formation of chronic
pancreatitis in the mouse.
We next determined whether exogenous expression Smad7 is able
to affect chronic pancreatitis induced by cerulein. We compared the
pathological changes of pancreas in 6 wild type mice and 23 Smad7
transgenic mice. The representative results are shown in Fig. 3. We
found that exogenous expression of Smad7 had a protective role in the
development of chronic pancreatitis. The loss of acinar cells in Smad7
transgenic mice was much less than the wild type animals. Moreover,
some areas in Smad7 transgenic mice were intact without acinar
atrophy. As collagen I is the main component of ﬁbrosis, we used
immunohistochemistry to determine the expression level of collagen I
in these mice. As shown in Fig. 4A, the staining of collagen I was
reduced in Smad7 transgenic mice in comparison with the wild typead7 in the pancreas. Wild type (A to D) and Smad7 transgenic mice (E to H) were treated
l changes of chronic pancreatitis were markedly reduced in the Smad7 transgenic mice.
Fig. 4. Decreases of collagen I expression by Smad7 in the pancreas. Pancreatic sections
from the wild type (A) and the Smad7 transgenic mice (B) treated with cerulein were
used in immunohistochemistry (IHC) to investigate the expression levels of collagen I.
Note that the level of collagen I was profoundly reduced in the Smad7 transgenic mice
in comparison with the wild type animals. Representative pictures from different mice
are shown. Magniﬁcation: ×400.
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by overexpression of Smad7 in the pancreas. In addition, we analyzed
the expression level of ﬁbronectin, another major ECM component
induced by TGF-β. As shown in Fig. 5, ﬁbronectin was signiﬁcantlyFig. 5. Decreased ﬁbronectin expression in Smad7 transgenic mice. Pancreatic sections
from the wild type (A) and the Smad7 transgenic mice (B) treated with cerulein were
used in IHC to examine the expression level of ﬁbronectin, a marker of ﬁbrosis.
Representative pictures from different mice are shown. Magniﬁcation: ×200. Fibrosis
area was measured by ImageJ's Analyze and Measure tool from NIH and is shown in C.
⁎⁎ indicated pb0.01 by Student's t-test.
Fig. 6. Decreased PSC activation in Smad7 transgenic mice. Pancreatic sections from the
wild type (A) and the Smad7 transgenic mice (B) treated with cerulein were used in IHC
to examine the level ofα-SMA, a marker of PSC activation. Representative pictures from
different mice are shown. Magniﬁcation: ×200 for the left panels and ×400 for the
panels. The relative level α-SMA staining as determined by densitometric analysis is
shown in C. ⁎⁎ indicated pb0.01 by Student's t-test.reduced in the pancreas when Smad7 was overexpressed. Therefore,
these data provided additional evidence that Smad7 is able to inhibit
ECM deposition in the pancreas.
We also analyzed PSCs in these mice, as PSC is the source of
pancreatic ﬁbrosis and TGF-β can cause ECM secretion by activating
PSCs [11,12]. We examined the expression of α-smooth muscle actin
(α-SMA), a marker of activated PSC in the pancreas after cerulein
injections. Our data reveals that activated PSCs were greatly reduced
in the Smad7 transgenic mice (Fig. 6). Thus the exogenous Smad7
appears to inhibit PSC activation through inhibition of TGF-β signaling
and thereby reduce the extent of pancreatic ﬁbrosis.
The molecular mechanism of chronic pancreatitis is not well
understood. Partly because of this, there is currently no cure to
pancreatitis except for pancreatectomy with limited success. Recent
studies have indicated that TGF-β signaling is closely implicated in the
development of ﬁbrosis in chronic pancreatitis. Tissue trauma in
chronic pancreatitis may stir inﬂammatory response which in turns
summons inﬂammatory cells into the pancreas. The inﬂammatory
cells secret inﬂammatory mediators including TGF-β, which activate
PSCs to secrete ECM. If the inﬂammation in the pancreas persists, the
increased ECM deposition would occupy the enlarged interlobular
space, accompanied by atrophy and loss of acinar cells. Several groups
have found that inhibition of TGF-β signaling leads to decrease of
activated PSCs and pancreatic ﬁbrosis [17–19]. As the major function
of TGF-β is to activate PSCs [4], we postulate that the decreased
staining of α-SMA by Smad7 overexpression (Fig. 6) is mainly due to a
decrease of PSC activation, instead of reducing the number of PSCs. In
addition, TGF-β has been shown to enhance deposition of ECM, a
major mechanism underlying the ﬁbrosis-promoting activity of TGF-
β. We believe that the major effect of Smad7 in reducing pancreatic
60 J. He et al. / Biochimica et Biophysica Acta 1792 (2009) 56–60ﬁbrosis is via inhibiting TGF-β-induced ECM deposition, rather than
accelerating the degradation of deposited ECM. Interestingly, Lee et al
recently showed that the RECK, a novel membrane-anchored MMP
inhibitor, can be maintained by TGF-β [22], indicating that TGF-β
signaling may promote ECM accumulation by preserving the protease
inhibitory activity of RECK. This is consistent with the ﬁnding that
Smad7 was able to reverse the RECK-maintaining activity of TGF-β
[22]. Nevertheless, our study provides another piece of evidence that
inhibition of intracellular TGF-β signaling by Smad7 also reduces
ﬁbrosis and activation of PSCs in cerulein-induced chronic pancrea-
titis. Therefore, increasing Smad7 expression in the pancreas could
potentially serve as new strategy to treat ﬁbrosis in chronic
pancreatitis.
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